Low-Dose Naltrexone and Microglia: A Different Drug at a Different Dose

Key Takeaways:

• In laboratory and rat studies, forms of naltrexone and naloxone blocked Toll-like receptor 4, an immune sensor on microglial cells, and mirror-image versions that cannot bind opioid receptors still reversed established nerve-injury pain, separating this anti-inflammatory action from opioid blockade.
• In a small crossover trial of 31 women with fibromyalgia, 4.5 milligrams of naltrexone daily reduced baseline pain by 28.8 percent versus 18.0 percent on placebo and was tolerated as well as placebo.
• A larger 2024 randomized trial of 99 women with fibromyalgia found that 6 milligrams daily for 12 weeks did not reduce pain significantly more than placebo, so the evidence for low-dose naltrexone remains early and mixed.

Naltrexone has been prescribed for decades at fifty milligrams a day, a dose that firmly blocks opioid receptors and is used to treat alcohol and opioid use disorders. Low-dose naltrexone, typically around a tenth of that amount, has drawn attention for an entirely different reason, and the story runs through the brain’s immune system. Microglia are the resident immune cells of the brain and spinal cord. In health they patrol quietly, but after nerve injury, infection, or ongoing stress they switch into an activated state and release inflammatory cytokines and other signals that make nearby pain-transmitting neurons more excitable. That process, sometimes called central sensitization, is one proposed reason pain can persist and spread long after an original injury heals, and it is a leading hypothesis in conditions such as fibromyalgia. One of the switches that turns microglia on is Toll-like receptor 4, or TLR4, a sensor built to detect danger signals from bacteria and damaged tissue. The theory behind low-dose naltrexone is that, at small doses, the drug acts less as an opioid blocker and more as a brake on this glial alarm system, quieting neuroinflammation rather than changing opioid signaling. A review of the evidence described it as potentially one of the first glial cell modulators used for chronic pain, while cautioning that its clinical use remains highly experimental.

The mechanism rests on a clever experiment. In rats with an established nerve-injury pain state, researchers showed that blocking TLR4 in the spinal cord reversed the pain, meaning the receptor helps maintain chronic pain and not only start it. They then tested the “plus” forms of naltrexone and naloxone, mirror-image molecules that do not bind opioid receptors at all, and found they blocked TLR4 on microglial cells and, given over several days, fully reversed the established pain; with the naloxone forms, spinal microglial activation was suppressed right alongside the pain. Because those molecules cannot touch opioid receptors, the result separated the anti-inflammatory action from opioid blockade. Human evidence is thinner. In a randomized, double-blind, placebo-controlled crossover trial, 31 women with fibromyalgia tracked their pain daily while taking 4.5 milligrams of naltrexone or placebo. Pain fell 28.8 percent from baseline on the drug versus 18.0 percent on placebo, life satisfaction and mood improved, fatigue and sleep did not, and 32 percent met the trial’s definition of a responder compared with 11 percent on placebo, with no serious side effects. A larger and longer test followed. In a 2024 randomized, double-blind trial, 99 women with fibromyalgia took 6 milligrams daily or placebo for 12 weeks, and pain intensity dropped by 1.3 points on a ten-point scale with naltrexone versus 0.9 points with placebo, a difference that was not statistically significant.

Does low-dose naltrexone help chronic pain?

The honest answer is that it might help some people, and the best current trial did not show a clear benefit on average. That combination is common for a treatment with a plausible mechanism, small early trials that looked encouraging, and a larger confirmatory study that came back neutral. It does not prove the mechanism wrong, and it may mean benefit is confined to a subgroup, depends on dose, or takes longer to appear, but those possibilities are hypotheses, not findings. Low-dose naltrexone is used off-label, is usually prepared by compounding pharmacies, and has no approved dose for pain, so it belongs in a careful conversation with a clinician rather than in a self-experiment. Because naltrexone is still an opioid blocker, it is not appropriate for anyone taking opioid pain medicines, and that interaction must be reviewed before it is ever considered. Its appeal is that in trials it has been well tolerated and inexpensive, which is why some patients with fibromyalgia and other centralized pain conditions decide, with their physician, that a monitored trial is reasonable. Even then, it works best as one piece of a broader plan: graded movement, protected sleep, stress regulation, and attention to the inflammatory load of diet and body weight, the same inputs that shape how reactive microglia become in the first place.

References:

1. Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., et al. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). The European Journal of Neuroscience, 28(1), 20-29.
2. Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451-459.
3. Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis and Rheumatism, 65(2), 529-538.
4. Due Bruun, K., Christensen, R., Amris, K., Vaegter, H. B., Blichfeldt-Eckhardt, M. R., Bye-Møller, L., et al. (2024). Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: A randomised, double-blind, placebo-controlled trial. The Lancet Rheumatology, 6(1), e31-e39.